Other studies evaluated ipilimumab combined with peptide vaccines (MART-1/gp100/tyrosinase with Montanide ISA 51 VG) as adjuvant setting in high-risk resected stages IIIC to IV melanoma. This evidence concerns the gene PMEL and melanoma.